These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 5779579

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Action mechanism and clinical success of Regelan (Clofibrate)].
    Fitzgerald JD.
    Wien Klin Wochenschr; 1967 Sep 29; 79(39):716-20. PubMed ID: 5595437
    [No Abstract] [Full Text] [Related]

  • 3. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
    De Gennes JL, Maunand B, Salmon D, Laudat P, Truffert J.
    Rev Atheroscler (Paris); 1966 Sep 29; 8(1):27-52. PubMed ID: 5961027
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clofibrate in the management of a case of lipoid dermato-arthritis: a clinical and metabolic study.
    Golding DN.
    Ann Rheum Dis; 1968 Sep 29; 27(5):475-6. PubMed ID: 5677165
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Familial hypercholesterolaemic xanthomatosis and coronary heart disease in a ten-year-old girl.
    Miettinen M.
    Ann Paediatr Fenn; 1967 Sep 29; 13(1):35-8. PubMed ID: 6079714
    [No Abstract] [Full Text] [Related]

  • 10. Essential hyperlipemia with xanthomatosis: effects of cholestyramine and clofibrate.
    Roe DA.
    Arch Dermatol; 1968 Apr 29; 97(4):436-45. PubMed ID: 5643239
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical experimentation with CPIB (with or without androsterone) in the treatment of hyperlipemia. Apropos of 35 cases].
    Warembourg H, Jaillard J.
    Lille Med; 1965 Apr 29; 10(4):431-6. PubMed ID: 5318637
    [No Abstract] [Full Text] [Related]

  • 12. Hypolipidemic agents--newly approved.
    Duncan GG.
    Pa Med; 1967 Aug 29; 70(8):75-6. PubMed ID: 6073724
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Atromid-S for the reduction of plasma lipids.
    Med Lett Drugs Ther; 1967 Jun 16; 9(12):45-7. PubMed ID: 6037633
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The therapeutic use of CPIB in pathological increase of the lipid constituents of the blood].
    Cloarec M, Cottet J, Etienne J, Loeper J.
    Sem Ther; 1965 Nov 16; 41(9):499-500. PubMed ID: 5877602
    [No Abstract] [Full Text] [Related]

  • 18. Clinical trial with ethyl-a-p-chlorophenoxyisobutyrate (Atromid-S) with special reference to white blood cell counts.
    Engström J.
    Acta Med Scand; 1966 Nov 16; 180(5):519-31. PubMed ID: 5332263
    [No Abstract] [Full Text] [Related]

  • 19. Laboratory indices in clofibrate therapy of juvenile-onset diabetes.
    Narduzzi JV, Danowski TS, Weir TF, Alley RA, Vester JW, Moses C.
    Clin Pharmacol Ther; 1967 Nov 16; 8(6):817-23. PubMed ID: 4862480
    [No Abstract] [Full Text] [Related]

  • 20. Clofibrate and androsterone effect on serum lipids.
    Orgain ES, Bogdonoff MD, Cain C.
    Arch Intern Med; 1967 Jan 16; 119(1):80-5. PubMed ID: 6015838
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.